Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.48 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20711215 | 0.85 | DPP4 (0.58) | — | |
| SCHEMBL20711304 | 0.84 | BCHE (0.44) | — | |
| SCHEMBL22837901 | 0.84 | AHCY (0.43) | — | |
| SCHEMBL20711329 | 0.82 | ADORA3 (0.52) | POLB | |
| SCHEMBL20711303 | 0.82 | POLB (0.51) | POLBENPP1P2RY1 | |
| SCHEMBL22837883 | 0.78 | ADORA3 (0.37) | — | |
| SCHEMBL20711233 | 0.78 | TRPM2 (0.58) | — | |
| SCHEMBL22837892 | 0.78 | TRPM2 (0.58) | — | |
| SCHEMBL22837893 | 0.78 | TRPM2 (0.58) | — | |
| SCHEMBL12379181 | 0.78 | TRPM2 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190038656-A1 | ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | Memorial Slooan-Kettering Cancer Center (US) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | ATIC, SLC35B2, ADORA1 | POLB 563/4885ENPP1 95/4885P2RY1 22/4885 |
| US-20190038656-A1 | ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ATIC, SLC35B2, ADORA1 | POLB 563/4885ENPP1 95/4885P2RY1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.